MRPL3 is identified as a prognostic biomarker and therapeutic target in lung adenocarcinoma via a lactylation-disulfidptosis gene signature model and experimental validation
BackgroundLung adenocarcinoma (LUAD), the most prevalent histological subtype of lung cancer, is a leading cause of global cancer mortality. Its pronounced heterogeneity poses a critical challenge, creating an urgent need for reliable biomarkers to accurately predict patient prognosis. Here, we focu...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2026-05-01
|
| Sarja: | Frontiers in Immunology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1772955/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|